EGFR and non-small cell lung carcinoma: Furthermore, the phase 2 JO25567 trial conducted in Japan enrolled more treatment-naïve patients with stage IIIB and IV NSCLC harboring activating EGFR mutations and showed a significantly longer PFS among patients who received combination erlotinib and bevacizumab than among those who received erlotinib alone [33].